If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksACC.L Regulatory News (ACC)

  • There is currently no data for ACC

Trading Update

9 Dec 2020 17:31

RNS Number : 1355I
Access Intelligence PLC
09 December 2020
 

Prior to publication, certain information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement, this information is now considered to be in the public domain.

 

Access Intelligence plc

("Access Intelligence" or the "Company")

Trading Update

 

 

Access Intelligence (AIM: ACC), the technology innovator delivering Software-as-a-Service ("SaaS") solutions for the PR, communications and marketing industries, announces an update on trading for year ended 30 November 2020.

 

The Company's growth rate has more than doubled in the second half of the year with strong new business and renewal rates underpinning excellent growth in Annual Contract Value ('ACV') of £2.82m. This compares to ACV growth of £1.06m in the first six months of the financial year, with all sub-brands seeing growth acceleration in the second half. New business sales in the year increased by 95 per cent. year on year and upsell increased by 52 per cent. year on year. Total ACV at 30 November 2020 was approximately £21.9 million.

 

New clients wins in the second half include Amazon, Automobili Lamborghini, Boots, British Retail Consortium, Comic Relief, European Food Safety Authority, Hulu, LinkedIn, Linklaters, McLaren Racing, Publicis, Saatchi & Saatchi, Unicredit and Veolia. The wins continue to demonstrate the increasing appeal of the Company's product portfolio across different sectors and territories.

 

The Board expect that total revenue for the financial year will be in the order of £19.1 million, compared to £13.4 million for the prior year.

 

Given the circumstances created by COVID 19, the year saw the board take a number of cost saving initiatives including the Company furloughing approximately 15% of staff, salary and fee reductions for the Board and employees for three months, and the curtailment of discretionary spending. Notwithstanding the global economic challenges faced in the year, the Board is delighted with the excellent growth trajectory demonstrated by the Company in the year and the Board remains focused on delivering against the longer-term growth opportunity. As part of this strategy the Board actively looks to explore new business opportunities through product enhancement and new technologies to complement the Group's suite of products. This strategy seeks to deliver organic growth complemented by acquisitions to capitalise on opportunities which enable the Group to accelerate its market position. In the course of this year, the Company has incurred non recurring costs of £2.4m including £1.2m of costs incurred as it evaluated potential M&A activity in-line with this strategy.

 

The Company continues to be in a good financial position and as at 30 November, net cash was approximately £1.4 million. In order to underpin the Group's finances and provide additional liquidity, the Company has secured a £2 million, three year facility under the Coronavirus Business Interruption Loan Scheme (CBILS). The facility can be drawn down during December 2020, has a 12-month interest-free period following drawdown and an interest rate of 2.03% plus LIBOR or replacement benchmark rate per annum on the drawn down amount thereafter. The funds are repayable in equal monthly instalments over 36 months and there will be no penalty for making early repayment of the facility. In addition, as the Company looks to accelerate its growth, the Company is separately announcing a placing to raise approximately £10 million today.

 

Christopher Satterthwaite, Non-Executive Chairman of the Company, said: 

"We reported 10% organic ACV growth in 2019 and saw that rise to 12% in the first half of 2020, in spite of the global COVID pandemic. Delivering annualised ACV growth of 30% in the second half of 2020 is an excellent achievement.

 

We've achieved these results thanks to colleagues adapting quickly and readily to new ways of working in challenging circumstances. I cannot praise their energy, focus and flexibility highly enough.

 

This positive performance demonstrates the strength of our product portfolio and our increasing global market presence.

 

We will be starting the financial year 2021 with confidence and a strong pipeline of opportunities."

 

For further information:

Access Intelligence plc 020 3426 4024

Joanna Arnold (CEO) / Mark Fautley (CFO)

finnCap Limited (Nominated Adviser and Broker) 020 7220 0500

Corporate Finance:

Marc Milmo / Kate Bannatyne / Kate Washington

Corporate Broking:

Alice Lane / Sunila de Silva

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFSSFWUESSEDE
Date   Source Headline
22nd Sep 20117:00 amRNSCobent Vendor Arrangements and Trading Update
22nd Aug 20114:25 pmRNSDirector/PDMR Shareholding
11th Jul 20117:00 amRNSNotice of Results
4th Jul 20117:00 amRNSSale of Solcara Limited
27th May 201112:16 pmRNSAnnual Report and Accounts
4th Apr 201112:45 pmRNSDirector/PDMR Shareholding
7th Mar 20117:00 amRNSFinal Results
31st Jan 20117:28 amRNSManagement Update
16th Dec 20107:00 amRNSTrading Update and Directorate Change
3rd Nov 20107:00 amRNSNominated adviser and broker change of name
31st Aug 20107:00 amRNSIssue of equity on conversion of Loan Notes
19th Jul 20107:00 amRNSHalf Yearly Report
23rd Jun 20107:00 amRNSNotice of Results
14th Apr 201012:55 pmRNSResult of AGM
31st Mar 20107:00 amRNSHolding(s) in Company
25th Mar 201012:08 pmRNSDirector Dealing and Exercise of Options
25th Mar 20107:50 amRNSNotice of AGM
3rd Mar 20106:26 pmRNSHolding(s) in Company
3rd Mar 20103:22 pmRNSIssue of Equity
2nd Mar 20109:06 amRNSDirector/PDMR Shareholding
1st Mar 20107:00 amRNSAcquisition
1st Mar 20107:00 amRNSPreliminary Results
23rd Feb 20107:00 amRNSNotice of results meeting
12th Jan 20107:00 amRNSTrading Statement
2nd Nov 20099:08 amRNSDirector/PDMR Shareholding
6th Oct 20098:52 amRNSIssue of Share Options
29th Jul 20091:30 pmRNSResult of General Meeting
10th Jul 20097:00 amRNSAdditional Convertible Loan Notes
1st Jul 20097:00 amRNSAcquisition and Convertible Loan Note
24th Jun 20097:00 amRNSHalf Yearly Report
15th Jun 20097:00 amRNSChange of Name of Nominated Adviser and Broker
1st May 20092:52 pmRNSResult of AGM
23rd Mar 20097:00 amRNSFinal Results
22nd Dec 20087:00 amRNSTotal Voting Rights
12th Dec 20087:00 amPRNDirectorate Change
9th Dec 20087:00 amRNSIssue of Equity
19th Nov 20087:00 amPRNShareholder Information
5th Nov 20087:01 amPRNDirectorate Change
5th Nov 20087:00 amRNSDisposal
5th Nov 20087:00 amPRNAcquisition of Solcara
31st Oct 20087:00 amPRNTotal Voting Rights
27th Oct 20087:00 amPRNDirectorate Change
20th Oct 200810:42 amPRNResult of EGM
24th Sep 20087:00 amRNSBoard Changes & Subscription
6th Aug 20087:00 amRNSInterim Results
21st Jul 20087:00 amRNSNotice of Results
6th Jun 20087:00 amRNSTrading Statement
5th Jun 20085:53 pmRNSTrading Statement
12th Mar 20087:00 amRNSChange in Shareholding
6th Mar 20087:00 amPRNFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.